Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 15, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: July 23, 2025
Plain language summary of the EVOKE-01 study of sacituzumab govitecan vs docetaxel in patients with non-small cell lung cancer.
Journal: Future oncology (London, England)
Published: May 15, 2025
Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: August 23, 2024
Sacituzumab Govitecan in Patients with Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results from the Phase II TROPiCS-03 Basket Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 02, 2024
Efficacy and Safety of Sacituzumab Govitecan in Patients With Advanced Solid Tumors (TROPiCS-03): Analysis in Patients With Advanced Endometrial Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 31, 2024
Patient-Reported Symptoms and Quality of Life With Sacituzumab Govitecan Versus Docetaxel in Metastatic NSCLC: The Phase 3, Randomized EVOKE-01 Trial.
Journal: JTO clinical and research reports
Published: July 16, 2024
Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2024
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: April 05, 2019
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 16, 2018
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Journal: The New England journal of medicine
Published: March 22, 2018
Last Updated: 09/26/2026